公开(公告)号：US20210332140A1

公开(公告)日：2021-10-28

申请号：US17194950

申请日：2021-03-08

申请人： argenx BVBA ,  VIB VZW ,  Universiteit Gent

发明人： Jean-Michel PERCIER ,  Christophe BLANCHETOT ,  Michael SAUNDERS ,  Hans DE HAARD ,  Sebastian VAN DER WONING ,  Emma PERSSON ,  Bart LAMBRECHT ,  Savvas SAVVIDES ,  Hamida HAMMAD ,  Kenneth VERSTRAETE

IPC分类号： C07K16/28 ,  G01N33/68

摘要： The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

公开(公告)号：US20200216528A1

公开(公告)日：2020-07-09

申请号：US16661783

申请日：2019-10-23

申请人： argenx BVBA

发明人： Christophe Frederic Jerome BLANCHETOT ,  Birgitte URSØ ,  Tine SKAK-NIELSEN ,  Malene BERTELSEN ,  Sebastian VAN DER WONING ,  Michael SAUNDERS ,  Johannes Joseph Wilhelmus DE HAARD

IPC分类号： C07K16/24 ,  C07K16/28 ,  A61P17/06 ,  A61P19/02 ,  A61P17/02 ,  C07K14/54 ,  C12N15/62

摘要： The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

公开(公告)号：US20230088269A1

公开(公告)日：2023-03-23

申请号：US17819161

申请日：2022-08-11

申请人： argenx BVBA

发明人： Christophe Frederic Jerome BLANCHETOT ,  Birgitte URSØ ,  Tine SKAK-NIELSEN ,  Malene BERTELSEN ,  Sebastian VAN DER WONING ,  Michael SAUNDERS ,  Johannes Joseph Wilhelmus DE HAARD

IPC分类号： C07K16/24 ,  C07K16/28 ,  A61P17/06 ,  A61P19/02 ,  A61P17/02 ,  C07K14/54 ,  C12N15/62

摘要： The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

公开(公告)号：US20190127459A1

公开(公告)日：2019-05-02

申请号：US16242760

申请日：2019-01-08

申请人： argenx BVBA

发明人： Christophe Frederic Jerome BLANCHETOT ,  Birgitte URSØ ,  Tine SKAK-NIELSEN ,  Malene BERTELSEN ,  Sebastian VAN DER WONING ,  Michael SAUNDERS ,  Johannes Joseph Wilhelmus DE HAARD

IPC分类号： C07K16/24 ,  A61P17/06 ,  A61P17/02 ,  A61P19/02 ,  C07K14/54 ,  C12N15/62

摘要： The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

公开(公告)号：US20200157207A1

公开(公告)日：2020-05-21

申请号：US16661757

申请日：2019-10-23

申请人： argenx BVBA

发明人： Christophe Frederic Jerome BLANCHETOT ,  Birgitte URSØ ,  Tine SKAK-NIELSEN ,  Malene BERTELSEN ,  Sebastian VAN DER WONING ,  Michael SAUNDERS ,  Johannes Joseph Wilhelmus DE HAARD

IPC分类号： C07K16/24 ,  C07K16/28 ,  C12N15/62 ,  C07K14/54 ,  A61P17/02 ,  A61P19/02 ,  A61P17/06

摘要： The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

公开(公告)号：US20190218310A1

公开(公告)日：2019-07-18

申请号：US16230326

申请日：2018-12-21

申请人： argenx BVBA

发明人： Sebastian VAN DER WONING ,  Christophe BLANCHETOT

IPC分类号： C07K16/46

CPC分类号： C07K16/468 ,  C07K16/46 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/64 ,  C07K2317/76

摘要： The present invention relates to bispecific and other multispecific antigen binding constructs. In certain aspects, the invention relates to bispecific antigen binding constructs comprising a single domain antibody (VHH) antigen binding region fused to an IgG Fc domain; a heavy chain-Fc domain portion of a conventional IgG antibody, and a light chain portion of a conventional IgG antibody. The bispecific antigen binding constructs of the invention are capable of targeting two different antigens separately or in a protein complex.